痰热清、伲福达等治疗尿毒症难治性肺部感染分析

Tanreqing and Nifedipini Treatment of Uremic Refractory Pulmonary Infection

目的:分析痰热清治疗尿毒症难治性肺部感染的临床效果。方法:选择我院于2013年11月—2016年10月间收治的59例尿毒症难治性肺部感染患者为研究主体,划分为A组和B组,分别是31例与28例。B组给予常规治疗,A组加用痰热清治疗。对比症状、体征缓解时间、临床疗效以及生活质量评分。结果:A组的咳嗽,咳脓痰缓解时间、体温正常时间和体征缓解时间均短于B组,对比差异明显,有统计学意义(P<0.05)。A组的治疗总有效率是96.77%,B组是71.43%,对比有差异,有统计学意义(P<0.05)。治疗前,两组患者生活质量评分差异不明显,对比无统计学意义(P>0.05);治疗后,A组患者生活质量评分为89.94 5.43,B组为70.71 5.10,A组显著优于B组,两组数据差异明显,对比具有统计学意义(P<0.05)。结论:为尿毒症难治性肺部感染患者采用痰热清治疗,可以促进病情好转,且临床疗效显著,可积极推广。

Objective:To analyze the clinical effect of Tanreqing in the treatment of refractory pulmonary infection in uremia.Methods:59 patients with refractory pulmonary infection who were treated in our hospital from November 2013 to October 2016 were selected as subjects,and divided into group a and group b,with 31 cases and 28 cases respectively.Group b was given routine treatment,and group a was treated with Tanreqing injection.The symptoms,signs of relief time,clinical efficacy and quality of life score were compared.Results:The cough in group a,the remission time of cough,the normal time of body temperature and the remission time of symptoms were shorter than those of group b,and the difference was significant(P<0.05).The total effective rate was 96%in group a and 71.43%in group b(P<0.05).Before treatment,the quality of life of the two groups of patients with no significant difference in scores,no statistical significance(P>0.05);After treatment,the quality of life of group a was 89.94 5.43,group b was 70.71 5.10,group a was significantly better than group b,the difference of data between the two groups was significant(P<0.05).Conclusion:Tanreqing injection for uremic patients with refractory pulmonary infection can promote the improvement of the disease,and the clinical effect is significant,can be actively promoted.